12:00 AM
Oct 31, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Sofosbuvir/velpatasvir/voxilaprevir: Phase III data

Top-line data from the open-label, international Phase III POLARIS-2 trial in 941 patients with chronic HCV genotypes 1-6 infection who were not previously treated with a direct-acting antiviral (DAA) showed that once-daily oral sofosbuvir/velpatasvir/voxilaprevir for 8 weeks missed the primary endpoint of non-inferiority to...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >